|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
This excerpt taken from the ELN 6-K filed Aug 28, 2009. 6 LEGAL
SETTLEMENT GAIN
For the first half of 2009, we recorded a legal settlement gain
of $18.0 million (2008: $Nil) related to a Settlement
Agreement and Release entered into by Elan and Watson in March
2009 to settle litigation with respect to Watsons
marketing of a generic version of Naprelan. As part of
the Settlement Agreement and Release, Watson stipulated that our
patent at issue is valid and enforceable and that Watsons
generic formulations of Naprelan infringed our patent. In
connection with the settlement, we received $18.0 million
from Watson in March 2009.
Table of Contents
|
| |||||||